GLP-1 drugs have reshaped the treatment landscape for obesity, Type 2 diabetes, and increasingly, cardiovascular disease itself, and their rapid rise has intensified pressure on sponsors to bring new metabolic treatments to market faster. But the patients enrolling in these trials are often already managing elevated cardiovascular risk before they take a single dose, and the drugs themselves can carry cardiac effects worth tracking closely. As metabolic drug development accelerates, continuous cardiac monitoring gives trial teams a way to capture that risk in real time rather than waiting for the next scheduled visit to catch it.
This blog will cover:
Patients enrolling in metabolic drug trials rarely arrive with metabolic disease alone. Obesity and type 2 diabetes are closely linked to cardiovascular risk through shared underlying mechanisms: insulin resistance, chronic inflammation, and hypertension all drive both metabolic dysfunction and cardiac complications simultaneously. By the time a patient qualifies for a weight loss or diabetes drug trial, many are already managing high blood pressure, abnormal cholesterol, or early signs of cardiac stress.
For trial teams, that existing risk profile makes cardiovascular safety monitoring a baseline requirement rather than an add-on consideration. Spot checks and scheduled assessments can confirm what's true at a single point in time, but they can't capture the full picture of how a patient's cardiac health is shifting over the course of a long study. Continuous monitoring fills that gap, giving teams the visibility they need to detect changes early and respond before they become safety events.
GLP-1 drugs add another layer of cardiac complexity to an already at-risk population. On one hand, trials have shown that some GLP-1s can reduce the risk of major adverse cardiac events in patients with established cardiovascular disease, which is part of what has made this drug class so closely watched by cardiologists and trial sponsors alike. On the other hand, GLP-1s are also associated with a modest increase in resting heart rate, and their effects on blood pressure, cardiac rhythm, and autonomic function are still being characterized as the drugs move into broader populations and longer treatment durations.
That combination of potential benefit and documented cardiac effect makes continuous monitoring particularly valuable in GLP-1 trials, where a periodic ECG or spot blood pressure check may not be enough to track how a patient's cardiac profile is evolving over weeks and months of treatment.
For a patient population carrying baseline cardiovascular risk and taking a drug class with documented cardiac effects, the case for continuous monitoring goes beyond convenience. A continuous ECG patch captures heart rate and heart rate variability in real time, giving trial teams an ongoing window into autonomic function that a scheduled site visit simply cannot provide.
This matters particularly for diabetic patients, where reduced heart rate variability is a recognized marker of cardiac autonomic neuropathy, a complication of longstanding or poorly controlled diabetes that affects how the nervous system regulates the heart. Tracking HRV, blood pressure, and SpO2 continuously over the course of a trial can surface changes that would otherwise go undetected between assessments.
Vivalink works with sponsors and CROs to integrate continuous, multivital monitoring into metabolic drug trials, helping teams build the cardiac safety infrastructure their protocols require from day one. Contact us to learn how our wearable devices can support your trial.
Copyright © 2026 VivaLNK, Inc. All Rights Reserved.
No Comments Yet
Let us know what you think